This Is Where AI Drug Deals Quietly Fall Apart.
AI-enabled drug transactions increasingly turn on more than patents and scientific merit. This article examines data provenance, IP ownership, collaboration terms, and model dependencies that can affect diligence, valuation, and deal readiness.
If You Don’t Own the Data, You Don’t Own Anything.
In AI-enabled drug discovery, enterprise value depends on more than the pipeline. Data ownership, licensing terms, model improvements, and platform dependencies can shape IP strategy, diligence, and commercialization.